University of Strathclyde

Other

The University of Chicago

The Secretary of State for Defence

University of Leeds

University of Sheffield

Institute for Systems Biology

Government of the United States

J. Craig Venter Institute

Apicomplexan Therapeutics, LLC

Craig Roberts

Rima McLeod

Leroy E Hood

Kamal El Bissati

Yong Zhou

Hernan Alejandro Lorenzi

Mark Hickman

QiGui Li

Martin McPhillie

Taek-Kyun Kim

Colin W G Fishwick

Fiona Roberts

Kai Hua Wang

Ethel Diane Williamson

Piotr Gornicki

Ying Zhou

Ernest J Mui

Paul Richard Ingram

Riccardo Vincenzo D'Elia

Stuart Woods

Jennifer J Johnson

David Ferguson

Michael Kirisits

Russell Lyons

Doug Mack

Benjamin Samuel

Ellen Zuther

Kai Wang

Fiona Luisa Henriquez

Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.

Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases

The invention relates to methods for the preparation of a pharmaceutical-vesicle formulation comprising steps of: preparing and processing vesicle components and a pharmaceutical agent to entrap the pharmaceutical agent in the vesicle and form a pharmaceutical-vesicle formulation, wherein the pharmaceutical-vesicle formulation is reconstituted in a known quantity of the pharmaceutical agent dissolved in a pharmaceutically-acceptable carrier to provide a biphasic pharmaceutical-vesicle formulation. The invention also relates to the associated pharmaceutical-vesicle formulations, pharmaceutical kits and uses as a medicament, in particular for the prevention or treatment of infection by bacteria such asand, and viruses such as Venezuelan Equine Encephalitis Virus (VEEV).

Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses

Disclosed herein; are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.

The present invention relates to compounds that modulate the shikimate pathway and/or a pathway branching from the shikimate pathway in members of the Amoebida Order. In particular these compounds may be useful in the treatment or prevention of diseases caused or contributed to by members of the Amoebida Order.

Antimicrobial compounds

This invention relates uses of chorismate synthase, a component components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, in assays to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding the enzymes and peptides, or promoters of these nucleotide sequences to which antibodies, antisense molecules and other inhibitors are directed. Diagnostic and therapeutic reagents and vaccines are developed based on chorismate synthase and its inhibitors.

Antimicrobial agents, diagnostic reagents, and vaccines based on unique Apicomplexan parasite components

Growing community of inventors

Glasgow, United Kingdom

Craig Roberts